Vigil Neuroscience, Inc. (VIGL)
Automate Your Wheel Strategy on VIGL
With Tiblio's Option Bot, you can configure your own wheel strategy including VIGL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VIGL
- Rev/Share 0.0
- Book/Share 1.4136
- PB 5.5814
- Debt/Equity 0.1949
- CurrentRatio 2.9653
- ROIC -1.1789
- MktCap 368238411.0
- FreeCF/Share -1.1619
- PFCF -6.8797
- PE -4.1909
- Debt/Assets 0.1185
- DivYield 0
- ROE -1.117
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | VIGL | Stifel | Buy | Hold | -- | $8 | May 28, 2025 |
| Initiation | VIGL | William Blair | -- | Outperform | -- | -- | Dec. 4, 2024 |
News
Wall Street Analysts Believe Vigil Neuroscience (VIGL) Could Rally 86.68%: Here's is How to Trade
Published: May 23, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at an 86.7% upside potential for Vigil Neuroscience (VIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Sanofi to Buy Vigil Neuroscience for About $470 Million
Published: May 21, 2025 by: WSJ
Sentiment: Positive
Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding a new investigational treatment for Alzheimer's disease to the French pharmaceutical company's pipeline.
Read More
Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
- Vigil's shareholders to receive up to $10.00 per share in cash, comprised of $8.00 per share in cash at closing and a non-tradeable contingent value right of $2.00 per share in cash following the first commercial sale of VG-3927 -
Read More
Sanofi to acquire Vigil Neuroscience in $470 million deal
Published: May 21, 2025 by: Reuters
Sentiment: Positive
Sanofi said on Thursday that it would acquire Vigil Neuroscience, a clinical-stage biotech company, for $8 per share in cash, valuing the deal at about $470 million.
Read More
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer's disease to the neurology pipeline
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer's disease to the neurology pipeline
Read More
Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates
Published: May 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
– On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – – Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer's disease in Q3 2025 – WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced financial results for the first quarter ending March 31, 2025, and provided updates on its recent progress.
Read More
Vigil Neuroscience (VIGL) Upgraded to Buy: Here's What You Should Know
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Vigil Neuroscience (VIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
About Vigil Neuroscience, Inc. (VIGL)
- IPO Date 2022-01-07
- Website https://www.vigilneuro.com
- Industry Biotechnology
- CEO Dr. Ivana Magovcevic-Liebisch J.D., Ph.D.
- Employees 69